Literature DB >> 12047362

CTLA-4 49 A/G dimorphism and type 1 diabetes susceptibility: a French case-control study and segregation analysis. Evidence of a maternal effect.

I Fajardy1, A Vambergue, C Stuckens, J Weill, P M Danze, P Fontaine.   

Abstract

Several studies have demonstrated an association of cytotoxic T lymphocyte-associated molecule 4 (CTLA-4) (IDDM 12) alanine 17 with type 1 diabetes, but we wished to study the parental effect of CTLA-4 49 A/G dimorphism in diabetic families. The CTLA-4 exon 1 polymorphism (49 A/G), HLA-DRB1 and insulin gene (INS) variable number tandem repeats (VNTR) were analysed in 134 type 1 diabetic patients vs. 273 control subjects. The segregation analysis for transmission was carried out in 70 informative diabetic families using the transmission distortion test (TDT). All genotyping was performed by PCR-RFLP. CTLA-4 49 G allele frequency was not increased in diabetic patients compared to controls (41 vs. 38%, not significant). The distribution of GG, AG and AA CTLA-4 genotypes was similar in the two groups (13, 57 and 30% vs. 11, 54 and 35%, respectively) and was independent of HLA-DRB1 or INS VNTR polymorphism. The CTLA-4 49 G allele showed weak distorted transmission to the diabetic offspring, whereas random transmission was observed in unaffected offspring. This distortion is attributable to a maternal effect (71% compared to the 50% expected ratio; tdt = 4.8; P < 0.03). The combined transmission of maternal CTLA-4 G with HLA-DRB1*03 (90%; tdt = 6.4; P < 0.01) and VNTR class I (80%; tdt = 5.4; P < 0.02) enhanced the susceptibility effect of each marker separately. We noted a slight CTLA-4 49 G and HLA-DRB1*04 distortion of transmission shared in paternal and maternal diabetic meiosis. In non-diabetic offspring, the CTLA-4 49 A allele confers a protective effect in the presence of maternal HLA-DRB1*03 and paternal HLA-DRB1*04 alleles. Despite the absence of a positive association of the CTLA-4 49 G allele with type 1 diabetes, our segregation analysis supports the hypothesis of a modulation by CTLA-4 49 G/A dimorphism of the susceptibility conferred by maternal HLA-DRB1*03 inheritance. This potential parental effect needs to be confirmed in a larger data set.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12047362     DOI: 10.1046/j.1365-2370.2002.00309.x

Source DB:  PubMed          Journal:  Eur J Immunogenet        ISSN: 0960-7420


  5 in total

1.  Analysis of thyroglobulin gene polymorphisms in patients with autoimmune thyroiditis.

Authors:  Mariela Caputo; Carina M Rivolta; Teresa Mories; Juan J Corrales; Purificación Galindo; Rogelio González-Sarmiento; Héctor M Targovnik; José M Miralles-García
Journal:  Endocrine       Date:  2010-03-18       Impact factor: 3.633

2.  Analysis of maternal-offspring HLA compatibility, parent-of-origin and non-inherited maternal effects for the classical HLA loci in type 1 diabetes.

Authors:  P G Bronson; P P Ramsay; G Thomson; L F Barcellos
Journal:  Diabetes Obes Metab       Date:  2009-02       Impact factor: 6.577

3.  Gestational respiratory infections interacting with offspring HLA and CTLA-4 modifies incident β-cell autoantibodies.

Authors:  Kristian F Lynch; Hye-Seung Lee; Carina Törn; Kendra Vehik; Jeffrey P Krischer; Helena Elding Larsson; Michael J Haller; William A Hagopian; Marian J Rewers; Jin-Xiong She; Olli G Simell; Jorma Toppari; Anette-G Ziegler; Beena Akolkar; Heikki Hyöty; Ezio Bonifacio; Åke Lernmark
Journal:  J Autoimmun       Date:  2017-09-21       Impact factor: 14.511

Review 4.  Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases.

Authors:  Monika C Brunner-Weinzierl; Holger Hoff; Gerd-R Burmester
Journal:  Arthritis Res Ther       Date:  2004-03-03       Impact factor: 5.156

5.  Common variants on cytotoxic T lymphocyte antigen-4 polymorphisms contributes to type 1 diabetes susceptibility: evidence based on 58 studies.

Authors:  Jingnan Wang; Lianyong Liu; Junhua Ma; Fei Sun; Zefei Zhao; Mingjun Gu
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.